Stress induces major depressive disorder by a neutral sphingomyelinase 2-mediated accumulation of ceramide-enriched exosomes in the blood plasma.
Behavior
Ceramide
Exosomes
Major depression
Neurogenesis
Neutral sphingomyelinase 2
Journal
Journal of molecular medicine (Berlin, Germany)
ISSN: 1432-1440
Titre abrégé: J Mol Med (Berl)
Pays: Germany
ID NLM: 9504370
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
25
06
2022
accepted:
17
08
2022
revised:
11
08
2022
pubmed:
1
9
2022
medline:
16
9
2022
entrez:
31
8
2022
Statut:
ppublish
Résumé
Major depressive disorder (MDD) is a very common, severe disease with a lifetime prevalence of ~ 10%. The pathogenesis of MDD is unknown and, unfortunately, therapy is often insufficient. We have previously reported that ceramide levels are increased in the blood plasma of patients with MDD and in mice with experimental MDD. Here, we demonstrate that ceramide-enriched exosomes in the blood plasma are increased in mice with stress-induced MDD. Genetic studies reveal that neutral sphingomyelinase 2 is required for the formation of ceramide-enriched exosomes in the blood plasma. Accordingly, induced deficiency of neutral sphingomyelinase 2 prevented mice from the development of stress-induced MDD. Intravenous injection of microparticles from mice with MDD or injection of ceramide-loaded exosomes induced MDD-like behavior in untreated mice, which was abrogated by ex vivo pre-incubation of purified exosomes with anti-ceramide antibodies or ceramidase. Mechanistically, injection of exosomes from mice with MDD or injection of ex vivo ceramide-loaded microparticles inhibited phospholipase D (PLD) in endothelial cells in vitro and in the hippocampus in vivo and thereby decreased phosphatidic acid in the hippocampus, which has been previously shown to mediate MDD by plasma ceramide. In summary, our data indicate that ceramide-enriched exosomes are released by neutral sphingomyelinase 2 into the blood plasma upon stress and mediate stress-induced MDD. KEY MESSAGES: Stress induces ceramide-enriched exosomes in the blood plasma. Ceramide-enriched exosomes mediate major depressive disorder (MDD). Deficiency of neutral sphingomyelinase 2 protects from stress-induced MDD. Neutralization or digestion of ceramide in exosomes prevents stress-induced MDD. Ceramide-enriched exosomes inhibit endothelial phospholipase D in the hippocampus.
Identifiants
pubmed: 36045177
doi: 10.1007/s00109-022-02250-y
pii: 10.1007/s00109-022-02250-y
pmc: PMC9470690
doi:
Substances chimiques
Ceramides
0
Sphingomyelin Phosphodiesterase
EC 3.1.4.12
Phospholipase D
EC 3.1.4.4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1493-1508Informations de copyright
© 2022. The Author(s).
Références
Acta Psychiatr Scand. 1997 Mar;95(3):212-21
pubmed: 9111854
N Engl J Med. 2008 Jan 3;358(1):55-68
pubmed: 18172175
Biochem J. 2015 Feb 1;465(3):371-82
pubmed: 25287744
Nat Neurosci. 2017 Dec;20(12):1752-1760
pubmed: 29184215
Atherosclerosis. 2015 Dec;243(2):560-6
pubmed: 26523994
Cell Mol Neurobiol. 2021 Oct 12;:
pubmed: 34637015
Adv Cancer Res. 2018;140:121-154
pubmed: 30060807
Cells. 2021 May 21;10(6):
pubmed: 34064233
Biochem Biophys Res Commun. 2012 Mar 9;419(2):321-5
pubmed: 22342718
Neuron. 2009 May 28;62(4):479-93
pubmed: 19477151
J Neurosci. 2000 Dec 15;20(24):9104-10
pubmed: 11124987
Int Immunopharmacol. 2020 Feb 20;82:106285
pubmed: 32088640
J Cell Sci. 2022 Mar 1;135(5):
pubmed: 35050379
J Biol Chem. 2001 Jun 8;276(23):20589-96
pubmed: 11279185
Recent Pat CNS Drug Discov. 2006 Jan;1(1):29-41
pubmed: 18221189
Pharmacogenomics J. 2022 Jul;22(4):211-222
pubmed: 35725816
Adv Biol Regul. 2018 Jan;67:141-147
pubmed: 28986032
PLoS One. 2011;6(8):e23852
pubmed: 21909365
J Biol Chem. 2022 Aug;298(8):102185
pubmed: 35753355
Nature. 2008 Oct 16;455(7215):894-902
pubmed: 18923511
Psychosom Med. 2009 Feb;71(2):171-86
pubmed: 19188531
Science. 2008 Feb 29;319(5867):1244-7
pubmed: 18309083
Hippocampus. 2006;16(3):239-49
pubmed: 16425236
J Neurochem. 2015 Jul;134(2):183-92
pubmed: 25925550
PLoS One. 2013 Sep 18;8(9):e73094
pubmed: 24058461
Ageing Res Rev. 2016 Dec;32:65-74
pubmed: 27238186
Oncogene. 2003 Oct 13;22(45):7070-7
pubmed: 14557812
J Clin Invest. 1974 Oct;54(4):919-25
pubmed: 4430721
Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50
pubmed: 18216770
Eur J Pharmacol. 2003 Jan 1;458(1-2):31-6
pubmed: 12498904
J Med Chem. 2008 Jan 24;51(2):219-37
pubmed: 18027916
Metabolism. 2019 Jun;95:65-76
pubmed: 30954559
Clin Chim Acta. 2021 Jul;518:110-115
pubmed: 33775701
Science. 2019 Apr 12;364(6436):
pubmed: 30975859
Biol Chem. 2019 Dec 18;401(1):31-46
pubmed: 31408430
Diabetes. 2009 Feb;58(2):337-43
pubmed: 19008343
Neuroscience. 2000;96(2):253-8
pubmed: 10683565
Addict Biol. 2020 Nov;25(6):e12847
pubmed: 31828921
J Lipid Res. 2020 Jun;61(6):896-910
pubmed: 32156719
Biol Psychiatry. 2010 Mar 1;67(5):446-57
pubmed: 20015486
Mol Psychiatry. 2018 Dec;23(12):2324-2346
pubmed: 30038230
Biol Psychiatry. 2000 Feb 15;47(4):351-4
pubmed: 10686270
Behav Brain Res. 2022 Aug 26;432:113987
pubmed: 35780959
Cell. 2019 Oct 31;179(4):864-879.e19
pubmed: 31675497
Psychopharmacology (Berl). 1985;85(4):387-404
pubmed: 2410942
Expert Opin Pharmacother. 2020 Jan;21(1):9-20
pubmed: 31663783
FEBS Open Bio. 2021 Oct;11(10):2678-2692
pubmed: 34043886
J ECT. 2017 Sep;33(3):e20-e21
pubmed: 28471771
Mol Psychiatry. 2021 Dec;26(12):7403-7416
pubmed: 34584229
Circ Res. 2019 Feb 15;124(4):564-574
pubmed: 30582458
Science. 2003 Aug 8;301(5634):805-9
pubmed: 12907793
Nat Med. 2013 Jul;19(7):934-8
pubmed: 23770692
Biol Chem Hoppe Seyler. 1994 Jul;375(7):447-50
pubmed: 7945993